Ascletis' Mitra Strategis Sagimet Mengumumkan Pasien Pertama yang Diberi Obat dalam Uji Klinis Fase III di Amerika Serikat untuk Denifanstat (ASC40) untuk Jerawat yang Parah hingga Berat

Clinical-stage biopharmaceutical company Sagimet Biosciences announced the administration of the first dose in its Phase III trial for denifanstat, also known as ASC40. The trial evaluates the efficacy and safety of the oral drug in treating patients suffering from moderate to severe acne vulgaris. This clinical advancement triggers a strategic milestone under the ongoing partnership between Sagimet and Ascletis Pharma. Positive clinical data from this late-stage study could pave the way for future regulatory submissions in major pharmaceutical markets. Investors in both partnering entities responded favorably to the operational progress in the dermatology pipeline. The trial represents a significant step in addressing unmet medical needs in chronic skin conditions through novel metabolic mechanisms.